Methylphenidate Hydrochloride Tablet, Extended Release
Product Images NDC 51407-925

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Methylphenidate Hydrochloride (NDC 51407-925). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Golden State Medical Supply, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

51407-924-01 (pl).jpg (51407 924 01 (pl))

51407-924-01 (pl).jpg (51407 924 01 (pl))
This text provides information about a medication containing 18 mg of methylphenidate hydrochloride in tablet form. It includes storage instructions, dosage information, and details for dispensing. The medication is an extended-release formula and the product is distributed by GSMS, Incorporated. It is essential to keep this medication in tight containers, away from children, and protected from moisture and humidity. Pharmacists should provide the Medication Guide separately to each patient when dispensing.*
FDA Label Image

51407-925-01 (pl).jpg (51407 925 01 (pl))

51407-925-01 (pl).jpg (51407 925 01 (pl))
The text provides information about methylphenidate hydrochloride tablets containing 27 mg. It includes dosing instructions, storage guidelines, and contact details for the marketer. The medication is an extended-release formulation and should be kept in tight containers to protect from moisture. Pharmacists are advised to dispense a Medication Guide to each patient.*
FDA Label Image

51407-926-01 (pl).jpg (51407 926 01 (pl))

51407-926-01 (pl).jpg (51407 926 01 (pl))
This text provides details about a medication containing 36 mg of methylphenidate hydrochloride in tablet form. The dosage information is advised to be checked in the accompanying prescribing information. It should be stored at a temperature range of 20° - 25°C to protect from moisture and humidity. The medication is dispensed in tight containers to keep it secure, and it is important to keep it out of reach of children. The product is marketed by GSMS, Incorporated in Camarillo, USA. It is an extended-release tablet and the packaging includes 100 tablets. Pharmacies are instructed to dispense a Medication Guide separately to each patient.*
FDA Label Image

51407-927-01 (pl).jpg (51407 927 01 (pl))

51407-927-01 (pl).jpg (51407 927 01 (pl))
This text provides information about methylphenidate hydrochloride extended-release tablets. Each tablet contains 54 mg of the active ingredient. It also includes storage instructions, dosage details, and a reminder to keep the medication out of reach of children. The text also mentions the pharmaceutical company, GSMS Inc., based in Camarillo, CA. Pharmacists are instructed to dispense a Medication Guide to each patient. The product is available in bottles containing 100 tablets.*
FDA Label Image

Structural Formula (Methylphenidate Hydrochloride Extended Release Tab 1)

FDA Label Image

Figure 1 (Methylphenidate Hydrochloride Extended Release Tab 2)

Figure 1 (Methylphenidate Hydrochloride Extended Release Tab 2)
This information shows the mean plasma concentrations of Methylphenidate in ng/mL for two different dosing regimens: 18mg once daily extended-release tablets and 5mg three times daily. The data reveals concentration levels at specific time points ranging from 16 to 32 ng/mL.*
FDA Label Image

Figure 2 (Methylphenidate Hydrochloride Extended Release Tab 3)

Figure 2 (Methylphenidate Hydrochloride Extended Release Tab 3)
This text appears to be a list of elements related to a study or clinical trial involving a medication called Methylphenidate Hydrochloride. The study involved three different phases or studies labeled as "Study1," "Study2," and "Study3," possibly evaluating the effects or efficacy of the medication. The medication was administered in the form of extended-release tablets once daily. The text also mentions "Symptoms" associated with the medication and "Placebo." It seems to indicate some numerical or graphical data with values such as "90 @1," "Week 4," and various symbols and numbers.*
FDA Label Image

Figure 3 (Methylphenidate Hydrochloride Extended Release Tab 4)

FDA Label Image

Tirgen Logo (Methylphenidate Hydrochloride Extended Release Tab 5)

FDA Label Image

Trigen Logo (Methylphenidate Hydrochloride Extended Release Tab 6)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.